RUBY News and Press, Rubius Therapeutics Inc. From 03/13/20

IDEAYA Biosciences (NASDAQ: IDYA ) initiated with Buy rating and $12 (192% upside) price target at Roth Capital. More news on: IDEAYA Biosciences, Inc., Menlo Therapeutics Inc., Amarin Corporation plc, Healthcare stocks news, Stocks on the move, , Read more ...

Image source: The Motley Fool. Rubius Therapeutics, Inc   (NASDAQ: RUBY) Q4 2019 Earnings Call Mar 12, 2020 , 8:00 a.m. ET Operator Continue reading

The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with their 2019 Q4 earnings Read more ...

Rubius Therapeutics, Inc. (RUBY) Q4 2019 Earnings Conference Call March 12, 2020 8:00 AM ET Company Participants Lori Melançon – Vice President of Corporate Communications and Investor Relations Pablo Cagnoni – Chief Executive Officer Christina Coughlin –...

Gainers: Greenland Technologies Holding (NASDAQ: GTEC ) +60% . More news on: Greenland Technologies Holding Corporation, Organogenesis Holdings Inc., Predictive Oncology Inc., Stocks on the move, , Read more ...

Rubius Therapeutics (NASDAQ: RUBY ): Q4 GAAP EPS of -$0.56 beats by $0.08 . Cash, cash equivalents and investments of $283.29M Press Release More news on: Rubius Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

AdaptHealth (NASDAQ: AHCO ) initiated with Buy rating and $17 (31% upside) price target at Stifel. More news on: AdaptHealth Corp., DURECT Corporation, InMed Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Dosing is underway in a Phase 1 clinical trial evaluating Rubius Therapeutics' ( RUBY -4.5% ) lead candidate RTX-134, an allogeneic off-the-shelf cell therapy, for the potential treatment of phenylketonuria (PKU), a rare inborn error of metabolism characterized by the buildup of the am...

CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dose...

RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration Rubius Manufacturing Facility Operational Nine Months Ahead of Schedule and Ready to Supply Future Clinical Trials Focus on Clinical Development to Advance Three Distinct Therapeutic...